Are Peptides Good
Independent · Evidence-based · No products sold

Are peptides good? Here's the honest answer.

Peptides are everywhere right now, and most of what you read is either hype, fear, or someone trying to sell you something. Here are the straightforward, honest answers. No fluff, no selling you anything: just what the research actually shows, what doctors and the FDA say, and how to explore them without getting burned.

Free to read. We don't sell peptides and we never link to gray-market vendors.

Every page is sourced from authorities like
Short answer Some peptides are proven, FDA-approved medicines — insulin and semaglutide are two examples with large human trials behind them. Others sold online as wellness compounds have almost no human data. Whether a peptide is "good" depends on which one, what it is approved for, and where it comes from. The category is neither good nor bad; the details decide.
New to peptides?

Start with the basics

Sixty seconds of plain English before the deeper stuff. If you already know what a peptide is, skip ahead.

A peptide is a short chain of amino acids, the same building blocks that make up proteins. Your body already makes thousands of them, including hormones like insulin. Most peptides work as signaling molecules that tell your cells what to do. The catch: "peptides" covers everything from FDA-approved medicines to unregulated vials sold online, so what matters is always which peptide, and where it comes from. A handful of peptide medicines have very strong evidence behind them: GLP-1 peptides like semaglutide (Ozempic, Wegovy) have helped millions of people reach a healthier weight, according to Harvard Health Publishing.1 Most other wellness peptides sold online do not have that level of evidence.

The full explainer: what are peptides?
Go deeper

The questions everyone actually asks

Four straight answers, each backed by named sources. Read the one that matches where you are.

The one distinction that matters

It's not the peptide. It's where you get it.

The same compound can come from a supervised medical channel or an unregulated seller. These two paths could not be more different.

Safer Licensed medical route

  • Prescription after a real medical intake
  • Made by a licensed compounding pharmacy
  • Purity and sterility to pharmacy standards
  • Dose set and adjusted by a clinician
  • Bloodwork and follow-up monitoring

Risky "Research use only" vendor

  • No prescription, no questions asked
  • Not intended or tested for human use
  • Purity and contents unverified
  • You guess the dose, often from forums
  • No monitoring if something goes wrong

This is the whole game. Most peptide horror stories trace back to the right column, not to peptides being inherently dangerous. See how to stay in the left column →

The evidence

What the research and regulators actually say

An evidence-based account of what is established, what is preliminary, and what remains unknown — sourced from the FDA, Stanford Medicine, Harvard Health, and published clinical trials.

The question "are peptides good?" is almost impossible to answer in the abstract, because the word "peptide" covers a range that stretches from some of the most studied medicines in human history to vials sold online with almost no human safety data. The evidence on that spectrum is not evenly distributed, and conflating one end with the other is the source of most of the confusion you'll find online.

The FDA-approved tier: roughly 100 therapeutics

Peptide medicines have a decades-long track record in formal medicine. According to Stanford Medicine, the FDA has approved roughly 100 different peptide therapeutics since injectable insulin first became available — covering conditions from diabetes to HIV-associated lipodystrophy to multiple sclerosis.4 These compounds went through the full regulatory process: human safety trials, large-scale efficacy studies, documented side effect profiles, and defined dosing guidelines before any patient received them.

The GLP-1 receptor agonists are the most visible recent example. Semaglutide, the active compound in Ozempic and Wegovy, completed a large phase III trial — the STEP 1 study — that enrolled 1,961 participants and ran for 68 weeks before the drug reached physicians. In that trial, 86.4 percent of participants in the treatment group achieved at least 5 percent weight loss, compared with 31.5 percent on placebo.5 That is what rigorous human evidence looks like: a defined population, a control group, a long timeline, and documented side effects weighed against measurable outcomes. A 2024 CDC National Health Interview Survey found that 26.5 percent of U.S. adults with diagnosed diabetes reported using GLP-1 injectable medications — a reflection of how rapidly this class has moved into mainstream clinical practice.6

The evidence-grade table: where commonly discussed peptides actually sit

Not all peptides are anywhere near that level of study. This table maps where the most commonly discussed compounds sit on the evidence spectrum — not based on marketing claims, but on the current state of published human data.

Peptide Human safety data available FDA status Evidence grade
Insulin 100+ years of clinical use; extensive data Approved (multiple indications) Highest — among the most studied molecules in medicine
Semaglutide (GLP-1) Multiple large phase III trials; 1,961 participants in STEP 1 alone Approved (obesity, type 2 diabetes) High — robust human efficacy and safety data
Tesamorelin Phase III trials completed Approved (HIV-associated lipodystrophy) High — within its approved indication
BPC-157 2 people in one pilot IV study (2025) Not approved; removed from most compounding Very limited — animal data only for most claims
TB-500 (Thymosin β-4 fragment) No published human safety trials Not approved; removed from most compounding No human data
CJC-1295 / Ipamorelin No published human safety trials; FDA flagged serious adverse events for Ipamorelin Not approved; Ipamorelin removed from compounding No human data; regulatory caution noted
GHK-Cu (injectable) No published human injection safety trials Not approved for injection; removed from compounding No human data for the injectable route

Why the source changes the risk more than the molecule

Even setting aside the evidence question, where a peptide comes from determines its practical safety in ways that the molecule itself does not. A large share of wellness peptides available online carry a "research use only" label. That label means the product is legally sold for in vitro laboratory research — not intended, tested, or regulated for human use. There is no federal requirement that a research-use-only product meet pharmaceutical-grade purity or sterility standards before it ships to a buyer.

The American Medical Association has specifically warned against self-injecting peptides obtained this way, citing contamination and dosing risks as the primary concerns.2 Published analytical chemistry research examining peptides sourced from suspected illegal internet pharmacies has found purity as low as 5 percent in certain cysteine-containing samples — meaning up to 95 percent of a vial's contents were impurities rather than the labeled compound. Several samples in that research contained arsenic at concentrations up to ten times the International Council for Harmonisation toxicity limit for injectable drugs.

Harvard Health Publishing notes that injectable peptides sold this way "could trigger abnormal immune system responses, leading to allergic reactions (including severe ones like anaphylaxis) or autoimmune issues in some people."1 This is not a risk that any standard side-effect list captures, because it relates to contamination and immune response rather than the labeled compound's known pharmacology.

A market growing faster than the evidence beneath it

U.S. peptide-related online searches hit an estimated 10.1 million per month in early 2026 — roughly five times the volume seen in 2020 — according to wellness industry tracking data. The commercial interest in peptides has grown dramatically and much faster than the clinical research that could justify most wellness applications.

This gap is part of what makes the category confusing. GLP-1 peptides like semaglutide are legitimately among the most significant metabolic medicines in recent history, with a substantial evidence base and FDA approval for defined indications. That genuine success has created a halo effect around the broader "peptide" category, even though most wellness peptides being sold online share nothing with semaglutide except belonging to the same molecular class.

As Harvard Health Publishing notes, online health claims about peptides "have not been vetted by any expert group, the FDA, or anyone else. The health claims are divorced from data." The evidence that exists for proven peptide medicines does not transfer to unapproved compounds simply because they share a label.

What the FDA has been doing since 2023

The regulatory picture for wellness peptides has shifted noticeably. In late 2023, the FDA moved 19 commonly used wellness peptides — including BPC-157, TB-500, and several growth-hormone-releasing compounds — off the list of substances that licensed compounding pharmacies could legally prepare, citing limited safety data and identified risks.7 In July 2026, an FDA advisory committee voted 8 to 6 (with one abstention) to recommend reconsidering some of those restrictions, a narrow margin that reflects how genuinely unsettled the evidence base remains even among the specialists who track it most closely.

The FDA's ongoing actions reflect the same distinction that matters throughout this site: the agency has approved roughly 100 peptide therapeutics that went through proper human testing, while simultaneously tightening access to compounds that have not. The two tracks exist simultaneously because "peptide" describes a molecular structure, not an evidence level. More on the regulatory picture is on our peptide legality page.

The questions worth asking first: before evaluating any specific peptide, ask two things — is this compound FDA-approved for the use case in question, and if not, what does the actual human evidence say? Those two questions will do more to clarify the picture than any marketing claim will.

How to evaluate any peptide claim

  • Check the approval status first. Is the compound FDA-approved? If yes, for what specific indication? Approval means the human evidence met a defined bar. Non-approval does not automatically mean unsafe, but it means the bar has not been met yet.
  • Ask what the human data actually shows. Animal studies are the starting point, not the endpoint. "Promising in rats" is meaningfully different from "studied in 1,961 people in a 68-week controlled trial." Ask which of those categories the compound you are researching falls into.
  • Evaluate the source, not just the compound. A licensed compounding pharmacy with a supervising physician provides purity testing, sterility assurance, and medical monitoring that a gray-market vendor cannot. The supply chain changes the practical risk profile even when the labeled compound is identical.
  • Be skeptical of certainty in either direction. Coverage of peptides tends to swing between "miraculous" and "all snake oil." Neither is accurate. Some peptides are well-evidenced medicines; most popular wellness peptides have thin or no human data. The distinction matters, and you deserve to know which category you are looking at.

Understanding what peptides actually are — as a class of molecules — is useful context before evaluating any specific compound. Our full explainer on what peptides are covers the biology, the vocabulary, and why the category is so broad. And if you are actively weighing whether to try a peptide, our guide on the safest way to try peptides walks through exactly how to evaluate a clinic and what to ask a provider.

Why trust this site

How we decide what goes on the page

We're not selling peptides, so we have no reason to oversell them. Here's the standard every page is held to, written and maintained by Dana Marsh, an independent health & science writer.

Named sources only

Every claim ties back to the FDA, a major medical institution, or peer-reviewed research, not to a supplement brand.

Animal vs human evidence

We say plainly when a result is only shown in mice. "Promising in a rat study" is not "proven in you."

No hype, no fear

We won't promise a peptide cures anything, and we won't pretend the whole category is a scam. Just the evidence.

Reviewed and dated

Every page shows when it was last reviewed, because the science and the regulations keep moving.

"When you're talking about peptides being promoted online, those health claims have not been vetted by any expert group, the FDA, or anyone else. The health claims are divorced from data."

— Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School, in Harvard Health Publishing (July 2026)1

Fast answers

Peptide questions, answered straight

Are peptides good for you?
It depends on which peptide, for what, and where it's from. Some are proven, FDA-approved medicines. Many wellness peptides have only early, mostly-animal research and aren't approved for human use. The biggest risk is usually the unregulated market, not the concept. Full safety breakdown →
Do peptides work for weight loss?
Some do, and they're FDA-approved: semaglutide (Ozempic, Wegovy) is a peptide with large human trials behind it. That's very different from an unapproved "fat-loss peptide" sold online with no human data. The label "peptide" covers both, so the source and approval status matter enormously. The weight-loss peptide evidence →
Are peptides safe to inject at home?
Self-injecting peptides bought without a prescription is exactly what doctors and the AMA warn against.2 Without a licensed pharmacy, purity testing, and monitoring, you can't verify what's in the vial or the right dose. The safer route is a licensed clinic. Here's how that works →
Are peptides legal?
Approved peptide drugs are legal by prescription. Many are sold as "research use only," which is legal to sell for lab research but not for human use, and the FDA has been tightening that gap in 2025–26.3 The legal details →
What are the side effects of peptides?
They vary by peptide, and can include injection-site reactions, water retention, blood-sugar changes, headaches, and fatigue. With unregulated products the larger risks are contamination and incorrect dosing, which no side-effect list fully captures. Full side-effect guide →
How many peptides has the FDA approved?
According to Stanford Medicine, the FDA has approved roughly 100 different peptide therapeutics since injectable insulin first became available.4 These cover conditions from diabetes to growth hormone deficiency to multiple sclerosis. That approval pathway — requiring human trials — is what separates them from the wellness peptides sold online. What peptides are, explained plainly →
Are collagen peptides the same as wellness peptides?
No. Collagen peptides are short chains of amino acids from hydrolyzed collagen, taken orally as a supplement. Injectable wellness peptides like BPC-157 or TB-500 are a different category entirely — different molecules, different routes, and a completely different evidence and regulatory situation. Peptides vs. collagen: what's different →

Sources

  1. Harvard Health Publishing — "Peptides: what they are, potential benefits, and safety concerns." Includes discussion of immune response risks and Dr. Pieter Cohen's assessment of unvetted online health claims.
  2. American Medical Association — "What doctors want patients to know about injectable peptides." Patient guidance on gray-market risks, contamination concerns, and the AMA's position on self-injection.
  3. U.S. Food & Drug Administration — compounding regulations and guidance on unapproved peptides, including the legal framework for bulk drug substances.
  4. Stanford Medicine News (August 2026) — "Peptides: science, facts, and expert advice." Includes expert analysis from Dr. Jonathan Long and Dr. Katrin Svensson, and the figure of roughly 100 FDA-approved peptide therapeutics.
  5. Wilding et al., NEJM (2021) — STEP 1 trial of semaglutide — once-weekly semaglutide in adults with overweight or obesity; 1,961 participants over 68 weeks. PMID 33567185.
  6. CDC/NCHS Data Brief No. 537 (2025) — GLP-1 medication use among U.S. adults with diagnosed diabetes, 2024 National Health Interview Survey.
  7. U.S. Food & Drug Administration — certain bulk drug substances that may present significant safety risks; includes Category 2 rationale for removed wellness peptides including BPC-157, TB-500, GHK-Cu, and Ipamorelin.

Thinking about trying peptides?

Read the one page that matters most before you spend a dollar: how to tell a legitimate, licensed provider from an unregulated seller, and the exact questions to ask.